Skip to main content

About Us

ElsaLys Biotech at a glance

ELSALYS BIOTECH is a clinical stage immuno-oncology company which designs and develops a new generation of therapeutic antibodies targeting tumors and their immune and/or vascular microenvironment.

To convert these novel targets into drug candidates, the Company is currently conducting 3 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease and that is currently benefitting of cohort ATU in France for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV.

Founded in 2013, ELSALYS BIOTECH is located in the heart of the European cluster LYON BIOPOLE. As announced in May 2020, the company is a wholly owned subsidiary of Mediolanum Farmaceutici Spa.

23
Average Year Of Experience
3
Programs
15
Academic Partners

Management team

Dr Christine Guillen, PharmD

CEO and Co-founder

After holding various positions in the R&D department of LFB, Christine Guillen join

Dr Jacques Mizrahi, PhD

Vice President R&D

Jacques Mizrahi joined ElsaLys Biotech in 2014 as a consultant acting Chief Scientif

Dr David Liens, MD

Chief Medical Officer

David Liens brings more than 20 years’ experience in the field of drug development an

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.